Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M T Lotze

Showing results (81-90 of 299) with videos related to

Pageof 30
Sort By:
Transplantation Proceedings|April 1, 1988
Cells invading tumors: strategies for the identification and expansion of tumor reactive lymphocytesM T Lotze, W G Ross, S Tomita, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|August 1, 1993
Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancerH J Zeh, S Hurd, W J Storkus, et al.
European Journal of Immunology|November 22, 1997
Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivoT Tüting, A B DeLeo, M T Lotze, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1995
In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccineY Suminami, E M Elder, M T Lotze, et al.
Journal of Biological Response Modifiers|April 1, 1990
Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killingE A Wiebke, M C Custer, S A Rosenberg, et al.
Annals of Surgical Oncology|August 24, 1999
Recent advances in melanoma staging and therapyK M McMasters, V K Sondak, M T Lotze, et al.
Cancer Research|August 27, 1999
Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12Y Nishioka, M Hirao, P D Robbins, et al.
Journal of Surgical Oncology|November 10, 1998
Distant skin and soft tissue metastases from sarcomasU N Rao, S H Hanan, M T Lotze, et al.
Immunology Today|December 1, 1995
TCR usage in CTLs recognizing melanoma/melanocyte antigensM J Maeurer, D M Martin, W J Storkus, et al.
Immunological Investigations|June 15, 2000
Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigenR B Mailliard, R M Dallal, Y I Son, et al.
Pageof 30

Showing results (81-90 of 299) with videos related to

Sort By:
Pageof 30
Transplantation Proceedings|April 1, 1988
Cells invading tumors: strategies for the identification and expansion of tumor reactive lymphocytesM T Lotze, W G Ross, S Tomita, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|August 1, 1993
Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancerH J Zeh, S Hurd, W J Storkus, et al.
European Journal of Immunology|November 22, 1997
Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivoT Tüting, A B DeLeo, M T Lotze, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1995
In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccineY Suminami, E M Elder, M T Lotze, et al.
Journal of Biological Response Modifiers|April 1, 1990
Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killingE A Wiebke, M C Custer, S A Rosenberg, et al.
Annals of Surgical Oncology|August 24, 1999
Recent advances in melanoma staging and therapyK M McMasters, V K Sondak, M T Lotze, et al.
Cancer Research|August 27, 1999
Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12Y Nishioka, M Hirao, P D Robbins, et al.
Journal of Surgical Oncology|November 10, 1998
Distant skin and soft tissue metastases from sarcomasU N Rao, S H Hanan, M T Lotze, et al.
Immunology Today|December 1, 1995
TCR usage in CTLs recognizing melanoma/melanocyte antigensM J Maeurer, D M Martin, W J Storkus, et al.
Immunological Investigations|June 15, 2000
Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigenR B Mailliard, R M Dallal, Y I Son, et al.
Pageof 30